Drug Res (Stuttg) 2024; 74(06): 269-279
DOI: 10.1055/a-2331-7061
Review

Bedaquiline: An Insight Into its Clinical Use in Multidrug-Resistant Pulmonary Tuberculosis

Badruddeen,
Asad Ahmad
1   Department of Pharmacy, Integral University, Lucknow, India
,
Juber Akhtar
1   Department of Pharmacy, Integral University, Lucknow, India
,
Mohammad Ahmad
1   Department of Pharmacy, Integral University, Lucknow, India
,
Mohammad Irfan Khan
1   Department of Pharmacy, Integral University, Lucknow, India
,
Rufaida Wasim
1   Department of Pharmacy, Integral University, Lucknow, India
,
Anas Islam
1   Department of Pharmacy, Integral University, Lucknow, India
,
Aditya Singh
1   Department of Pharmacy, Integral University, Lucknow, India
› Institutsangaben

Research funding This research did not receive any specific grant from any funding agencies in the public, commercial, or not-for-profit sectors.
Preview

Abstract

Every year, the World Health Organization reports 500,000 new cases of drug-resistant tuberculosis (TB), which poses a serious global danger. The increased number of XDR-TB and MDR-TB cases reported worldwide necessitates the use of new therapeutic approaches. The main issues with the antitubercular medications now in use for the treatment of multidrug-resistant tuberculosis are their poor side effect profile, reduced efficacy, and antimicrobial resistance. One possible remedy for these problems is bedaquiline. The need for better treatment strategies is highlighted by the strong minimum inhibitory concentrations that bedaquiline (BDQ), a novel anti-TB medicine, exhibits against both drug-resistant and drug-susceptible TB. Bedaquiline may be able to help with these problems. Bedaquiline is a medication that is first in its class and has a distinct and particular mode of action. Bedaquiline is an ATP synthase inhibitor that is specifically directed against Mycobacterium tuberculosis and some nontuberculous mycobacteria. It is metabolized by CYP3A4. Bedaquiline preclinical investigations revealed intralesional drug biodistribution. The precise intralesional and multi-compartment pharmacokinetics of bedaquiline were obtained using PET bioimaging and high-resolution autoradiography investigations. Reduced CFU counts were observed in another investigation after a 12-week course of therapy. Meta-analyses and systematic reviews of phase II trials on bedaquilineʼs efficacy in treating drug-resistant tuberculosis in patients reported higher rates of cure, better culture conversion, and lower death rates when taken in conjunction with a background regimen. Here is a thorough medication profile for bedaquiline to aid medical professionals in treating individuals with tuberculosis.



Publikationsverlauf

Eingereicht: 04. Februar 2024

Angenommen: 06. Mai 2024

Artikel online veröffentlicht:
05. Juli 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14,70469 Stuttgart, Germany